According to filings with the U.S. Securities and Exchange Commission, Kyverna Therapeutics is raising $200,000,000.00 in new funding. About Kyverna Therapeutics: Kyverna Therapeutics is a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyvernas pipeline includes KYV-101, a fully human, autologous chimeric antigen receptor (CAR) T-cell therapy with properties well suited for use in B cell-driven autoimmune diseases and KYV-201, a fully human, allogeneic CAR T-cell therapy. By offering more than one mechanism for taming autoimmunity, and with patients currently in treatment for multiple indications in the U.S. and Europe, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated.

To learn more about Kyverna Therapeutics, visit http://kyvernatx.com/

Contact:
Peter Maag, Chief Executive Officer
510-626-8331
https://www.linkedin.com/in/petermaag/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.